[en] INTRODUCTION: Demographic and clinical variables were examined in a post hoc analysis of the PROlonged Migraine Prevention with Topiramate (PROMPT) study to determine potential contribution to relapse. METHODS: After a six-month open-label (OL) topiramate phase, patients were randomised to continue topiramate or switch to placebo in a six-month double-blind (DB) phase. 'Relapse' was investigated in terms of change in monthly migraine days after randomisation compared with the month before randomisation, and was analysed during the first ('initial relapse') and last month ('sustained relapse') of the DB phase. More than 40 potential predicting factors were entered into analyses of variance and covariance. RESULTS: For initial relapse, variable-by-treatment interactions were significant for the Headache Impact Test (HIT-6) at DB baseline, and decline in acute medication intake or reporting of 'anxiety' in the OL phase. For sustained relapse, no statistically significant interactions were observed. CONCLUSION: Relapse after topiramate discontinuation in migraine prophylaxis appears to be unaffected by patient characteristics or baseline migraine frequency.
Disciplines :
Neurosciences & behavior Neurology
Author, co-author :
Schoenen, Jean ; Université de Liège - ULiège > Département des sciences biomédicales et précliniques > Neuro-anatomie
Reuter, Uwe
Diener, Hans*-Christoph
Pfeil, Joop
Schwalen, Susanne
Schauble, Barbara
van Oene, Joop
Language :
English
Title :
Factors predicting the probability of relapse after discontinuation of migraine preventive treatment with topiramate.
Publication date :
2010
Journal title :
Cephalalgia
ISSN :
0333-1024
eISSN :
1468-2982
Publisher :
Blackwell Science, Osney Mead Oxford, United Kingdom
scite shows how a scientific paper has been cited by providing the context of the citation, a classification describing whether it supports, mentions, or contrasts the cited claim, and a label indicating in which section the citation was made.
Bibliography
Dahlof C., Linde M. One-year prevalence of migraine in Sweden: a population-based study in adults. Cephalalgia 2001 ; 21: 664-671. (Pubitemid 32762789)
Lipton RB, Stewart WF, Diamond S., Diamond ML, Reed M. Prevalence and burden of migraine in the United States: data from the American Migraine Study II. Headache 2001 ; 41: 646-657. (Pubitemid 32777747)
Geraud G., Lanteri-Minet M., Lucas C., Valade D. French guidelines for the diagnosis and management of migraine in adults and children. Clin Ther 2004 ; 26: 1305-1318. (Pubitemid 39445352)
Evers S., Áfra J., Frese A., Goudsby PJ, Linde M., May A., et al. EFNS guideline on the drug treatment of migraine-report of an EFNS task force. Eur J Neurol 2006 ; 13: 560-572. (Pubitemid 43873628)
Steiner TJ, MacGregor EA, Davies PTG. Guidelines for all doctors in the diagnosis and management of migraine and tension-type headache. London: British Association for the Study of Headache, 2004.
Diener HC, Agosti R., Allais G., Bergmans P., Bussons G., Davies B., et al. Cessation versus continuation of 6-month migraine preventive therapy with topiramate (PROMPT): a randomised, double-blind, placebo-controlled trial. Lancet Neurol 2007 ; 6: 1054-1062. (Pubitemid 350123606)
Rothrock JF, Parada VA, Drinkard R., Zweifler RM, Key KF Predictors of a negative response to topiramate therapy in patients with chronic migraine. Headache 2005 ; 45: 932-935. (Pubitemid 41045372)
Taylor AP, Adelman JU, Freeman MC Efficacy of duloxetine as a migraine preventive medication: possible predictors of response in a retrospective chart review. Headache 2007 ; 47: 1200-1203. (Pubitemid 47457773)
Similar publications
Sorry the service is unavailable at the moment. Please try again later.
This website uses cookies to improve user experience. Read more
Save & Close
Accept all
Decline all
Show detailsHide details
Cookie declaration
About cookies
Strictly necessary
Performance
Strictly necessary cookies allow core website functionality such as user login and account management. The website cannot be used properly without strictly necessary cookies.
This cookie is used by Cookie-Script.com service to remember visitor cookie consent preferences. It is necessary for Cookie-Script.com cookie banner to work properly.
Performance cookies are used to see how visitors use the website, eg. analytics cookies. Those cookies cannot be used to directly identify a certain visitor.
Used to store the attribution information, the referrer initially used to visit the website
Cookies are small text files that are placed on your computer by websites that you visit. Websites use cookies to help users navigate efficiently and perform certain functions. Cookies that are required for the website to operate properly are allowed to be set without your permission. All other cookies need to be approved before they can be set in the browser.
You can change your consent to cookie usage at any time on our Privacy Policy page.